Hanmi Hits Jackpot Again, This Time With Janssen
This article was originally published in PharmAsia News
Executive Summary
Hanmi's run of major licensing out deals is continuing apace. Just a few days after announcing a huge diabetes licensing agreement with Sanofi, the South Korean pharma firm has landed another global pact worth up to $915m for its long-acting GLP/GCG analog for diabetes and obesity, this time with Janssen.